Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 6,646 | 13,631 | 63,533 | 96,300 | 55,846 |
| Gross Profit | 6,646 | 13,631 | 63,533 | 96,300 | 55,846 |
| Operating Expenses | 154,350 | 223,907 | 254,044 | 404,686 | 272,840 |
| Operating Income | -147,704 | -210,276 | -190,511 | -308,386 | -216,994 |
| Other Income | 11,389 | 24,014 | 29,583 | 26,665 | 4,843 |
| Pre-tax Income | -136,315 | -186,262 | -160,928 | -281,721 | -212,151 |
| Net Income Continuous | -136,315 | -186,262 | -160,928 | -281,721 | -212,151 |
| Net Income | $-136,315 | $-186,262 | $-160,928 | $-281,721 | $-212,151 |
| EPS Basic Total Ops | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 |
| EPS Basic Continuous Ops | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 |
| EPS Diluted Total Ops | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 |
| EPS Diluted Continuous Ops | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 |
| EPS Diluted Before Non-Recurring Items | -1.15 | -1.51 | -1.64 | -2.91 | -2.36 |
| EBITDA(a) | $-138,409 | $-200,394 | $-176,431 | $-292,208 | $-202,082 |